3 Top Biotech News Of The Week (22 Oct 2022) - Oculis, LLY, AKUS, JAZZ, ZYME
1) Another ophthalmology acquisition: Oculis. SA and European Biotech Acquisition Corp. announce business combination agreement
The resultant company, Oculis Holding SA will work to accelerate the development of Oculis’s differentiated ophthalmology pipeline therapeutics for diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma.
Oculis’ pipeline includes